---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-171997"
form_type: "8-K"
ticker: null
cik: "0001845337"
company_name: "Day One Biopharmaceuticals, Inc."
filed_at: "2026-04-23T23:59:59+00:00"
generated_at: "2026-05-15T04:37:16.148900+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Servier completes $2.5B acquisition of Day One Biopharma; shares to be delisted

## Summary
- Tender offer expired with 88,180,910 shares (85.34%) validly tendered; all conditions met.
- Merger completed; stockholders received $21.50 per share cash, ~$2.5B equity value.
- Trading halted on Nasdaq; delisting and deregistration initiated via Form 25 and Form 15.
- All prior directors and officers removed; replaced by Servier appointees David K. Lee and Danielle Button.
- Company equity plans, ESPP, and at-market sales agreement terminated effective at closing.

## SEC filing metadata
- accession: 0001193125-26-171997
- form_type: 8-K
- cik: 0001845337
- company_name: Day One Biopharmaceuticals, Inc.
- filed_at: 2026-04-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.02, 2.01, 3.01, 5.01, 5.03, 3.03, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845337/000119312526171997/0001193125-26-171997-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845337/000119312526171997/d27888d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-171997
- JSON: https://secwatch.observer/filing/0001193125-26-171997.json
- Plain text: https://secwatch.observer/filing/0001193125-26-171997.txt

## Source-grounded claims
- claim_id: 4baf129f29ae151899753c253947683a3155847d
  claim: Day One Biopharmaceuticals, Inc.: Amended and restated certificate of incorporation effective at the Effective Time of the merger.
  evidence_excerpt: Pursuant to the Merger Agreement, as of the Effective Time, the Company’s certificate of incorporation, as in effect immediately prior to the Effective Time, was amended and restated in its entirety (the “ Amended and Restated Certificate of Incorporation ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845337/000119312526171997/0001193125-26-171997-index.htm
- claim_id: c2d3e52ea045f171ae676d1bd364be7d75d9b4a0
  claim: Day One Biopharmaceuticals, Inc.: Bylaws of Purchaser became the bylaws of the Company effective at the Effective Time.
  evidence_excerpt: In addition, pursuant to the Merger Agreement, as of the Effective Time, the bylaws of Purchaser, as in effect immediately prior to the Effective Time, became the bylaws of the Company (the “ Amended and Restated Bylaws ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845337/000119312526171997/0001193125-26-171997-index.htm
- claim_id: 98e68dc92e3c63ebd664d2f970fad93bae12d289
  claim: Day One Biopharmaceuticals, Inc. underwent a change of control involving Servier Pharmaceuticals LLC (Parent), Servier Detroit Inc. (Purchaser), and Servier S.A.S. (Guarantor) for $21.50 per share in cash (closed 2026-04-23).
  evidence_excerpt: tender offer (the “ Offer ”) to purchase all of the issued and outstanding shares of common stock of the Company, par value $0.0001 per share (the “ Shares ”), at a price of $21.50 per share (the “ Offer Price ”), net to the seller in cash, without interest thereon, and less any applicable tax withholding, upon the terms and subject to the conditions set
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845337/000119312526171997/0001193125-26-171997-index.htm
- claim_id: dc2051da2b3877bfe231dd9def97f142a20445ea
  claim: Day One Biopharmaceuticals, Inc. terminated Equity Distribution Agreement with Piper Sandler & Co. and JonesTrading Institutional Services LLC (effective 2026-04-20).
  evidence_excerpt: on April 20, 2026, the Company provided written notice to Piper Sandler & Co. and JonesTrading Institutional Services LLC as sales agents (together, the “ Agents ”), of its election to terminate the Equity Distribution Agreement, dated June 1, 2022, between the Company and the Agents (the “ Sales Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845337/000119312526171997/0001193125-26-171997-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.